<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466958</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-USA-000620</org_study_id>
    <nct_id>NCT02466958</nct_id>
  </id_info>
  <brief_title>Trial of Levomilnacipran in Geriatric Depression</brief_title>
  <acronym>LMIL</acronym>
  <official_title>Double-blind Placebo-controlled Trial of Levomilnacipran in Geriatric Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to
      placebo for the treatment of depression in older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12-week pilot double-blind comparison of levomilnacipran (FETZIMA) to placebo for the
      treatment of geriatric depression. The investigators are interested in assessing the efficacy
      of levomilnacipran (LMIL) to placebo (PBO), and exploring the effects of antidepressant
      response on brain connectivity and neuroplasticity. This pilot study is designed to determine
      any differences in the efficacy, safety and tolerability of levomilnacipran compared to
      placebo, and to perform dose finding (20-120 mg per day) in 60 older depressed adults. The
      investigators anticipate that the LMIL will be superior to PBO in improving levels of
      depressive symptoms and rates of remission, as well as improving cognition, apathy, and
      quality of life. This proposal expands the investigator's focus on the biomarkers of
      neuroplasticity that have been used in several prior studies and demonstrated responsivity to
      antidepressant treatment. The purpose is to examine this directly in 60 older adults with
      major depression. This proposed trial will also serve as a pilot study to estimate the
      efficacy and tolerability of the drug in older depressed adults, and the dose-finding in this
      population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HDRS) scores</measure>
    <time_frame>Measured at each visit for 12 weeks</time_frame>
    <description>scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression Scale (CGI) scores</measure>
    <time_frame>Measured at each visit for 12 weeks</time_frame>
    <description>scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Geriatric Depression (GDS) scores</measure>
    <time_frame>Measured at each visit for 12 weeks</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Measured at each visit for 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>levomilnacipran (FETZIMA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levomilnacipran</intervention_name>
    <description>antidepressant</description>
    <arm_group_label>levomilnacipran (FETZIMA)</arm_group_label>
    <other_name>FETZIMA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>an inactive drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 years of age or older

          -  The presence of a major depressive disorder diagnosed according to the DSM-V criteria

          -  A 24-item Hamilton Rating Scale for Depression (HAMD) score of 17 or higher at
             baseline

          -  Mini-Mental State Exam (MMSE) score &gt; 24.

        Exclusion Criteria:

        Subjects will be excluded if they had 1) any current and/or lifetime history of other
        psychiatric disorders (except unipolar depression with or without comorbid generalized
        anxiety disorder), or 2) recent unstable medical or neurological disorders; 3) any
        disabilities preventing participation in the study or in the MRI; 4) diagnosis of dementia;
        5) acute suicidality; 6) subjects with known allergic reactions to milnacipran,
        uncontrolled narrow angle glaucoma, seizures, poorly-controlled hypertension or ischemic
        changes on ECG, serotonin syndrome, or the recently used MAOIs within last 4 weeks; 7)
        ineligible for MRI (e.g., metal in the body or claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Lavretsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Lavretsky, M.D.</last_name>
    <phone>310-794-4619</phone>
    <email>hlavrets@ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Semel Institute - Neuropsychiatric Institute (NPI)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Lavretsky, MD</last_name>
      <phone>310-794-4619</phone>
      <email>hlavrets@ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Helen Lavretsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Helen Lavretsky, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>depressed</keyword>
  <keyword>older adults</keyword>
  <keyword>antidepressants</keyword>
  <keyword>depression</keyword>
  <keyword>MDD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

